Progress of pomalidomide for relapsed/refractory multiple myeloma
10.3760/cma.j.cn115356-20220414-00109
- VernacularTitle:泊马度胺在复发难治多发性骨髓瘤中的研究
- Author:
Xiangbiao FANG
1
;
Jinlian LI
;
Wanchuan ZHUANG
Author Information
1. 蚌埠医学院附属连云港市第二人民医院血液内科，连云港 222000
- Keywords:
Multiple myeloma;
Pomalidomide;
Immunomodulatory drugs;
Recurrence;
Refractory;
Drug therapy, combination
- From:
Journal of Leukemia & Lymphoma
2023;32(10):634-637
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a plasma cell malignant proliferative hematological tumor. At present, a variety of drugs including immunomodulators (IMiD) and proteasome inhibitors (PI) have been used to treat MM, and the progression-free survival time of patients has been significantly prolonged. Because the immune dysfunction of MM patients has not been fundamentally corrected, most of them will eventually relapse and develop drug resistance. Pomalidomide, a third-generation IMiD, has achieved a high response rate in clinical trials of patients with relapsed/refractory multiple myeloma (RRMM) who did not respond to lenalidomide or bortezomib. This article reviews the mechanism of pomalidomide and the efficacy and safety of relevant clinical trials, so as to investigate the treatment measures for RRMM.
